TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
TEVA PHARMACEUTICAL INDUSTRIES LTD
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$41.31−0.19 (-0.46%)
Close on Oct 19, 2026
- Market cap
- $48.13B
- P/E (TTM)
- 68.9
- Dividend yield
- –
Share price
+$22.00 (+113.9%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TEVA PHARMACEUTICAL INDUSTRIES LTD saw revenue fall 15.2% to $14.10B over the twelve months to Jun 30, 2026. Operating income rose 79.3% to $1.60B, moving the operating margin from 5.4% to 11.4%. Free cash flow was $1.35B, up 51.5% from a year earlier.
Revenue
$14.10B
-15.2% vs. a year earlier
Operating income
$1.60B
+79.3% vs. a year earlier
Free cash flow
$1.35B
+51.5% vs. a year earlier
EPS, diluted
$0.60
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $48.13B
- P/E ratio
- 68.9
- Price to sales
- 3.41
- Price to book
- 6.21
- Dividend yield
- –
- Free cash flow yield
- 2.80%
Fundamentals
- Revenue
- $14.10B
- Net income
- $706.00M
- EPS, diluted
- $0.60
- Free cash flow
- $1.35B
- Book value per share
- $6.65
- Diluted shares
- 1.17B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$14.10B-15.2% YoY
Gross profit
$9.09B+10.1% YoY
Operating income
$1.60B+79.3% YoY
Net income
$706.00M
EPS, diluted
$0.60
Free cash flow
$1.35B+51.5% YoY
Reported periodTrailing twelve months